

Synthesis of *anti* and *syn* Hydroxy-*iso*-Evoninic Acids

Sarah A. Warren,^a Stephen Stokes,^b Christopher S. Frampton,^c Andrew J. P. White^a and Alan C. Spivey*^a

^aDepartment of Chemistry, Imperial College, London, SW7 2AY, UK, ^bAstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, ^cPharmorphix® Solid State Services, Sigma-Aldrich Group, 250 Cambridge Science Park, Milton Road, Cambridge, CB4 0WE, UK.

a.c.spivey@imperial.ac.uk


SUPPORTING INFORMATION

General Directions	2
Synthetic procedures for compounds 2 and 6-12	3-10
References	10
HPLC Chromatograms	11-12
NMR Spectra	13-34

General Directions


All reactions were performed under anhydrous conditions, in oven-dried glassware and under a nitrogen atmosphere. *Anhydrous Solvents*: MeCN, Et₂O, CH₂Cl₂ and THF were used directly following passage under nitrogen through Al₂O₃ columns in a Grubbs dry-solvent system (Innovative Technology Inc.). MeOH was used after distillation over CaH₂. *Reagents*: These were purchased from commercial sources and handled according to COSHH regulations. *Chromatography*: Flash chromatography (FC) was performed on silica gel (Merck Kieselgel 60 F₂₅₄ 230-400 mesh) and reverse phase chromatography on C18 silica gel (Fluka Kieselgel 90 F₂₅₄ 230-400 mesh). Thin Layer Chromatography (TLC) was performed on Merck aluminium-backed plates pre-coated with silica (0.2 mm, 60 F254) which were visualized either by quenching of ultraviolet fluorescence ($\lambda_{\text{max}} = 254$ nm) or by charring with KMnO₄ TLC dip. *Melting points*: were determined on a Kofler hot stage. *Infra red spectra*: were recorded as neat liquids on Perkin-Elmer Paragon 1000 Fourier transform spectrometer. Only selected absorbances (ν_{max}) are reported. *¹H NMR spectra*: These were recorded at 400 MHz on a Bruker AMX-400 instrument. Chemical shifts (δ_{H}) are quoted in parts per million (ppm) and referenced to the residual solvent peaks (CHCl₃ or HOD). Coupling constants (J) are reported to the nearest 2 significant figures. *¹³C NMR spectra*: These were recorded at 100 MHz on a Bruker AMX-400 instrument. Chemical shifts (δ_{C}) are quoted in ppm and referenced to the residual solvent peaks (CHCl₃ or HOD). *Mass spectra*: Low resolution mass spectra (m/z) were recorded on either a VG platform II or VG AutoSpec spectrometers, with only molecular ions (M⁺, MH⁺, MNH₄⁺) and major peaks being reported with intensities quoted as percentages of the base peak. High Resolution Mass Spectrometry (HRMS) measurements are valid to ± 5 ppm.

Diethyl 1-ethoxycarbonyl-1,4-dihydroxy-3-methylpyridine-4-phosphonate, **9**



3-Picoline (3 mL, 30.8 mmol, 1 eq.) was dissolved in MeCN (23 mL) and cooled to 0 °C. Ethyl chloroformate (2.95 mL, 30.8 mmol, 1 eq.) was added dropwise and the red solution was stirred at 0 °C for 40 min. P(OEt)₃ (4.96 mL, 30.8 mmol, 1 eq.) was added dropwise and the solution was allowed to warm to room temperature and stirred for a further 17 h, after which time, a colour change to yellow was observed. The mixture was concentrated *in vacuo* to afford *phosphonate* **9** (9.25 g, 30.5 mmol, 99%) as a yellow oil. *R*_f 0.21 (MeOH/CH₂Cl₂, 1:19); *v*_{max}/cm⁻¹ 2982 (CH₃), 1716 (C=O), 1312 (C-N), 1018 (C-O), 958 (phosphonate), 746 (P-O-C); δ_H (CDCl₃, 400 MHz) 6.72 (1H, bd, *J* 42 Hz, NCH), 6.53 (1H, bd, *J* 46 Hz, NCH), 4.78 (1H, bd *J* 24 Hz, NCHCH), 4.08 (2H, q, *J* 7.2 Hz, NCO₂CH₂), 3.95 (4H, m, P(O)OCH₂), 3.14 (1H, dd, *J* 27 and 4.7 Hz, PCH), 1.69 (3H, d, *J* 2.1 Hz, NCHCCH₃), 1.17-1.11 (9H, OCH₂CH₃); δ_c (CDCl₃, 100 MHz) 170.73 (s), 124.74 (d, *J* 27 Hz), 120.73 (d), 110.48 (d, *J* 46 Hz), 101.24 (d, *J* 46 Hz), 62.30 (t), 60.06 (t), 39.31 (d, *J* 145 Hz), 20.66 (q), 14.17 (q), 13.92 (q); δ_p (CDCl₃, 160 MHz) 21.20 (d, *J* 26 Hz); MS (ESI) *m/z* 230 ([M-COOEt]⁺), 180 (9), 162 (12); HRMS (ESI) 230.0941 calcd for C₁₀H₁₇NO₃P⁺ ([M-COOEt]⁺), found 230.0940, Δ = -0.4 ppm.


(±)-3-Methyl-4-[(*E*)-pent-2-en-4-yl]pyridine, **8**



Phosphonate **9** (9.74 g, 30.45 mmol, 1 eq.) was dissolved in THF (60 mL) and cooled to -78 °C. ⁿBuLi (1.6 M in THF, 20.9 mL, 33.5 mmol, 1.1 eq.) was added dropwise and the brown solution was stirred at -78 °C for 40 min. 4-Bromo-2-pentene¹ (5 g, 33.5 mmol, 1.1 eq.) in THF (5 mL) was added dropwise and after 30 min the reaction mixture was allowed to warm to 0 °C and stirred for another 40 min. The mixture was cooled down to -78 °C again and ⁿBuLi (1.6 M in THF, 41.8 mL, 67.0 mmol, 2.2 eq.) was added. After addition the solution was allowed to warm to 0 °C and stirred for another 45 min. Et₂O (20 mL) was added, followed by water (15 mL). The mixture was concentrated *in vacuo* to leave a orange/yellow liquid. Purification by FC (1:9 to 1:3, EtOAc/hexane) afforded *alkene* **8** (2.60 g, 16.1 mmol, 53%) as a pale yellow liquid. *R*_f 0.18 (EtOAc/hexane, 3:7); *v*_{max}/cm⁻¹ (neat) 2965 (CH₃), 2929 (CH₃), 2874 (CH₃), 1593 (C=C), 1451 (pyridine), 1404 (pyridyl), 966 (CH), 834 (CH); δ_H (CDCl₃, 400 MHz) 8.36 (1H, d, *J* 5.1 Hz, NCHCH), 8.31 (1H, s, NCH), 7.07 (1H, d, *J* 5.1 Hz, NCHCH), 5.33-5.38 (2H, CHCHCH₃), 3.58 (1H, p, *J* 6.9 Hz, ArCH), 2.27 (3H, s, ArCH₃), 1.66 (3H,


dt, J 6.1 and 1.2 Hz, CHCHCH₃), 1.29 (3H, d, J 7.1 Hz, ArCHCH₃); δ_c (CDCl₃, 100 MHz) 152.97 (s), 150.81 (d), 147.81 (d), 133.78 (d), 130.99 (s), 125.02 (d), 120.92 (d), 37.52 (d), 20.01 (q), 17.88 (q), 16.08 (q); MS (ESI) m/z 162 (MH⁺, 100), 155 (4), 150 (4), 147 (4); HRMS (ESI) 162.1277 calcd for C₁₁H₁₆N⁺ (MH⁺), found 162.1275, Δ = -1.2 ppm.

3-Methyl-4-[(2*S**,3*S**,4*S**)-2,3-epoxypentan-4-yl]pyridine and Methyl-4-[(2*S**,3*S**,4*R**)-2,3-epoxypentan-4-yl]pyridine, **11**



Alkene **8** (2.60 g, 16.1 mmol, 1 eq.) was dissolved in a mixture of THF (25 mL) and water (25 mL) and cooled to 0 °C. NBS (2.77 g, 16.1 mmol, 1 eq.) was added turning the solution yellow. After stirring at 0 °C for 1 h, NaHCO₃ (sat. aq., 30 mL) was added. The aqueous solution was extracted with CH₂Cl₂ (5 × 20 mL) and the combined extracts dried over MgSO₄ and then concentrated *in vacuo* to leave a crude mixture of bromohydrins **10** as a cream colored solid. MeCN (20 mL) was added, followed by 1M NaOH (20 mL) and the solution was heated at 65 °C for 1 h. MeCN was removed *in vacuo* and the remaining aqueous solution was extracted with CH₂Cl₂ (4 × 60 mL). The combined organic extracts were dried over MgSO₄ then concentrated *in vacuo* to afford epoxide **11** (2.40 g, 13.6 mmol, 84%, *dr* 52:48) as a clear oil. R_f 0.49 (MeOH/CH₂Cl₂, 1:9); $\nu_{\max}/\text{cm}^{-1}$ (neat) 2970 (CH), 1594 (pyridyl), 1404 (CH₃), 1381 (CH₃), 902 (epoxide), 834 (epoxide). **(2*S**,3*S**,4*S**)-epoxide **11** (major component):** δ_H (CDCl₃, 400 MHz) 8.43 (1H, d, J 5.2 Hz, NCHCH), 8.38 (1H, s, NCH), 7.20 (1H, d, J 5.1 Hz, NCHCH), 2.97 (1H, p, J 6.8 Hz, ArCH), 2.87-2.79 (2H, CHO), 2.31 (3H, s, ArCH₃), 1.35-1.28 (6H, CHCH₃); δ_c (CDCl₃, 100 MHz) 150.94 (d), 150.09 (s), 147.83 (d), 131.49 (s), 120.92 (d), 62.46 (d), 53.47 (d), 36.21 (d), 17.52 (q), 16.73 (q), 16.34 (q). **(2*S**,3*S**,4*R**)-epoxide **11** (minor component):** δ_H (CDCl₃, 400 MHz) 8.42 (1H, d, J 5.1 Hz, NCHCH), 8.39 (1H, s, NCH), 7.16 (1H, d, J 5.1 Hz, NCHCH), 3.06 (1H, p, J 7.1 Hz, ArCH), 2.87-2.79 (2H, CHO), 2.32 (3H, s, ArCH₃), 1.35-1.28 (6H, CHCH₃); δ_c (CDCl₃, 100 MHz) 151.03 (d), 150.45 (s), 147.90 (d), 131.04 (s), 121.16 (d), 62.74 (d), 53.47 (d), 36.54 (d), 17.47 (q), 16.73 (q), 16.31 (q). MS (ESI) m/z 178 (MH⁺, 100), 155 (3), 150 (3); HRMS (ESI) 178.1226 calcd for C₁₁H₁₆NO⁺ (MH⁺), found 178.1228, Δ = +1.1 ppm.


(2*R**,3*S**,4*S**)- and (2*R**,3*S**,4*R**)-4-(3-Methylpyridin-4-yl)pentane-2,3-diol, **12**



Epoxide **11** (1.60 g, 9.02 mmol, 1 eq., *dr* 52:48) was dissolved in MeCN (19 mL) and water (9.6 mL). HClO₄ (60% aq., 1.6 mL) was added dropwise and the solution was stirred at room temperature for 40


h. The solution was neutralised with sat. NaHCO₃ (sat. aq.) then concentrated *in vacuo* to remove all MeCN. The remaining aqueous solution was extracted with CH₂Cl₂ (4 × 30 mL) and the combined organic extracts were dried over MgSO₄, then concentrated *in vacuo* to leave a pale yellow oil. Purification by FC (MeOH/CH₂Cl₂, 1:19) afforded *1,2-diol 12* (1.469 g, 7.52 mmol, 83%, *dr* 52:48) as a clear oil. R_f 0.34 (MeOH/CH₂Cl₂, 1:9); ν_{max}/cm⁻¹ (neat) 3331 (OH), 2969 (CH₃), 2926 (CH₃), 1600 (pyridyl), 1074 (C-O), 734 (pyridyl). **(2R*,3S*, 4S*)-diol 11 (major component)**: δ_H (CDCl₃, 400 MHz) 8.40-8.30 (2H, NCH), 7.16 (1H, d, *J* 5.2 Hz, NCHCH), 4.00 (1H, qd, *J* 6.4 and 3.7 Hz, CHOHCH₃), 3.87 (1H, dd, *J* 9.0 and 3.6 Hz, ArCHCHOH), 3.19-3.07 (1H, ArCH), 2.37 (3H, s, ArCH₃), 1.19 (3H, d, *J* 7.0 Hz, ArCHCH₃), 1.16 (3H, d, *J* 6.3 Hz, CHOHCH₃); δ_C (CDCl₃, 100 MHz) 152.42 (s), 150.49 (d), 147.35 (d), 132.43 (s), 121.06 (d), 78.61 (d), 68.00 (d), 37.05 (d), 16.99 (q), 16.64 (q), 16.01 (q). **(2R*,3S*, 4R*)-diol 11 (minor component)**: δ_H (CDCl₃, 400 MHz) 8.40-8.30 (2H, NCH), 7.21 (1H, d, *J* 5.1 Hz, NCHCH), 3.81 (1H, dd, *J* 7.2 and 4.4 Hz, ArCHCHOH), 3.71 (1H, qd, *J* 6.3 and 4.5 Hz, CHOHCH₃), 3.19-3.07 (1H, ArCH), 2.33 (3H, s, ArCH₃), 1.34 (3H, d, *J* 6.9 Hz, ArCHCH₃), 1.30 (3H, d, *J* 6.3 Hz, CHOHCH₃); δ_C (CDCl₃, 100 MHz) 152.09 (s), 150.90 (d), 147.42 (d), 130.86 (s), 121.69 (d), 77.46 (d), 68.17 (d), 36.47 (d), 17.56 (q), 16.62 (q), 16.28 (q). MS (ESI) *m/z* 196 (MH⁺, 100), 179 (4), 178 (7), 150 (3); HRMS (ESI) 196.1332 calcd for C₁₁H₁₈NO₂ (MH⁺), found 196.1336, Δ = +2.4 ppm.

(±)-4-(3-Methylpyridin-4-yl)pentane-2,3-dione, 7




Oxalyl chloride (464 μL, 3.21 mmol, 2.2 eq.) in CH₂Cl₂ (2 mL) was cooled to -78 °C. DMSO (278 μL, 6.42 mmol, 4.4 eq) was added and the solution stirred for 5 min. 1,2-Diol **12** (290 mg, 1.49 mmol, 1 eq., *dr* 52:48) in CH₂Cl₂ (1.5 mL) was added dropwise and the solution was stirred for a further 15 min. Triethylamine (1.24 mL, 8.94 mmol, 6 eq.) was added dropwise and after 5 min the reaction mixture was quickly transferred to a short silica column and eluted with CH₂Cl₂. Purification by FC (CH₂Cl₂ to 1:99, MeOH/CH₂Cl₂) afforded *1,2-diketone 7* (270 mg, 1.41 mmol, 95%) as a bright yellow liquid. R_f 0.45 (MeOH/CH₂Cl₂, 1:19); ν_{max}/cm⁻¹ (neat) 2982 (CH₃), 2930 (CH₃), 1716 (C=O), 1594 (pyr); δ_H (CDCl₃, 400 MHz) 8.59 (1H, s, NCH), 8.52 (1H, d, *J* 5.6 Hz, NCHCH), 7.31 (1H, d, *J* 5.6 Hz, NCHCH), 4.84 (1H, q, *J* 7.0 Hz, ArCH), 2.54 (3H, s, ArCH₃), 2.34 (3H, s, COCH₃), 1.45 (3H, d, *J* 7.0 Hz, ArCHCH₃); δ_C (CDCl₃, 100 MHz) 197.72 (s), 196.89 (s), 151.56 (d), 147.90 (d), 146.13 (s), 131.68 (s), 121.19 (d), 40.43 (d), 24.34 (q), 16.22 (q), 15.94 (q); MS (ESI) 192 (MH⁺, 100), 193 (16), 233 (7), 251 (6); HRMS (ESI) 192.1019 calcd for C₁₁H₁₄NO₂⁺ (MH⁺), found 192.1020, Δ = +0.5 ppm.

(2*R,3*S**)- and (2*S**,3*S**)-Methyl 2-hydroxy-2-methyl-3-(3-methylpyridin-4-yl)butanoate, 6a and 6b (Table 1, entry 3)**




Freshly prepared 1,2-diketone **7** (223 mg, 1.17 mmol, 1 eq.) was dissolved in MeOH (25 mL) and ZnCl₂ (203 mg, 1.23 mmol, 1 eq.) was added. The mixture was stirred at 40 °C for 18 h then concentrated *in vacuo* to leave a yellow oil. CH₂Cl₂ (20 mL) was added followed by NaHCO₃ (sat. aq., 15 mL). The organic layer was extracted and the aqueous layer was further extracted with CH₂Cl₂ (3 x 15 mL) and the combined organic extracts were dried over MgSO₄ and concentrated *in vacuo* to leave a pale yellow oil. Purification by FC (MeOH/CH₂Cl₂, 1:49) afforded *esters 6a and 6b* (235 mg, 1.05 mmol, 90%, *dr* 35:65) as a pale yellow oil. *R_f* 0.47 (MeOH/CH₂Cl₂, 1:9); $\nu_{\max}/\text{cm}^{-1}$ (neat) 3505 (OH), 1730 (C=O), 1596 (pyr), 1452 (CH₃), 1255 (CH), 1175 (C-O), 1116 (C-O), 840 (C-O-C); **(2*R**,3*S**)-ester 6a (minor component)**: δ_{H} (CDCl₃, 400 MHz) 8.40-8.35 (2H, NCH), 7.49 (1H, d, *J* 5.2 Hz, NCHCH), 3.89 (3H, s, OCH₃), 3.43 (1H, q, *J* 7.0 Hz, ArCH), 2.38 (3H, s, ArCH₃), 1.20 (3H, s, COHCH₃), 1.18 (3H, d, *J* 7.0 Hz, ArCHCH₃); δ_{C} (CDCl₃, 100 MHz) 177.30 (s), 150.60 (d), 149.45 (s), 147.38 (d), 131.81 (s), 123.08 (d), 76.87 (s), 53.12 (q), 40.53 (d), 24.59 (q), 16.90 (q), 16.20 (q). **(2*S**,3*S**)-ester 6b (major component)**: δ_{H} (CDCl₃, 400 MHz) 8.40-8.35 (2H, NCH), 7.47 (1H, d, *J* 5.2 Hz, NCHCH), 3.54 (3H, s, OCH₃), 3.35 (1H, q, *J* 7.2 Hz, ArCH), 2.30 (3H, s, ArCH₃), 1.55 (3H, s, COHCH₃), 1.35 (3H, d, *J* 7.0 Hz, ArCHCH₃); δ_{C} (CDCl₃, 100 MHz) 176.69 (s), 150.64 (d), 150.53 (s), 147.46 (d), 130.73 (s), 122.05 (d), 76.42 (s), 52.41 (q), 40.90 (d), 25.31 (q), 16.24 (q), 14.92 (q); MS (ESI) *m/z* 224 (MH⁺, 100), 225 (13); HRMS (ESI) 224.1281 calcd for C₁₂H₁₈NO₃⁺ (MH⁺), found 224.1281, Δ = 0.0 ppm.

(-)-(2*R*,3*S*)-Methyl 2-hydroxy-2-methyl-3-(3-methylpyridin-4-yl)butanoate, 6a




After the above procedure a small sample of (-)-(2*R*,3*S*)-ester **6a** was isolated as colourless laths by chiral HPLC using an analytical IC column (see pages 11 and 12). Data as above. mp 54-56 °C (CH₂Cl₂); $[\alpha]_{\text{D}}^{25}$ -8.4 (*c* = 0.33, CH₂Cl₂). For single crystal X-ray structure determination including absolute configuration determination by Flack parameter analysis see separate Supporting Information file.

(+)-(2*S*,3*S*)-Methyl 2-hydroxy-2-methyl-3-(3-methylpyridin-4-yl)butanoate, 6b



After the above procedure a small sample of (+)-(2*S*,3*S*)-ester **6b** was isolated as colourless shards by chiral HPLC using a semi-prep OD-H column (see pages 11 and 12). Data as above. mp 55-57 °C (CH₂Cl₂); [α]_D²⁵ +11.2 (*c* = 0.92, CH₂Cl₂). For single crystal X-ray structure determination including absolute configuration determination by Flack parameter analysis see separate Supporting Information file.


(2*R**,3*S**)- and (2*S**,3*S**)-2-Hydroxy-2-methyl-3-(3-methylpyridin-4-yl)butanoic acid



Esters **6** (19 mg, 0.0851 mmol, *dr* 45:55[†]) were dissolved in MeOH (1.9 mL) and 2 M NaOH (1.9 mL) was added. The solution was stirred at 65 °C for 2 h after which time it had turned pale yellow. The solution was acidified to pH 5 with 1 M HCl then concentrated *in vacuo* to leave a white solid. MeCN (10 mL) was added and the solution was sonicated for 15 min. The resulting suspension was purified by reverse phase C18 FC (MeCN) to afford 2-hydroxy-2-methyl-3-(3-methylpyridin-4-yl)butanoic acid (16 mg, 0.0764 mmol, 89%, *dr* 45:55) as a white solid. R_f 0.15 (MeCN/H₂O, 4:1); mp 108-109 °C (MeCN); ν_{max}/cm⁻¹ (neat) 3379 (OH), 2974 (CH), 1721 (C=O), 1636 (pyr), 1488 (pyr), 1254 (CH), 1167 (C-O), 829. (**2*R**,3*S**)-acid (minor component)**: δ_H (D₂O, 400 MHz) 8.54 (1H, s, NCH), 8.49 (1H, d, *J* 6.0 Hz, NCHCH), 8.08 (1H, d, *J* 6.2 Hz, NCHCH), 3.77 (1H, q, *J* 6.5 Hz, ArCH), 2.68 (1H, s, CCH₃OH), 2.54 (3H, s, ArCH₃), 1.26 (3H, d, *J* 7.7 Hz, ArCHCH₃), 1.22 (3H, s, CCH₃OH); δ_C (D₂O, 100 MHz) 161.58 (s), 146.80 (s), 137.21 (d), 139.62 (d), 136.38 (d), 125.70 (s), 48.03 (s), 40.59 (d), 22.62 (q), 15.26 (q), 13.14 (q). (**2*S**,3*S**)-acid (major component)**: δ_H (D₂O, 400 MHz) 8.48 (1H, s, NCH), 8.45 (1H, d, *J* 5.5 Hz, NCHCH), 8.17 (1H, d, *J* 5.9 Hz, NCHCH), 3.70 (1H, q, *J* 6.5 Hz, ArCH), 2.51 (1H, s, CCH₃OH), 2.48 (3H, s, ArCH₃), 1.58 (3H, s, CCH₃OH), 1.33 (3H, d, *J* 7.0 Hz, ArCHCH₃); δ_C (D₂O, 100 MHz) 162.86 (s), 146.80 (s), 139.67 (d), 136.85 (d), 136.73 (d), 124.95 (s), 48.03 (s), 40.63 (d), 23.32 (q), 15.78 (q), 14.18 (q); MS (ESI) *m/z* 208 (22), 210 (MH⁺, 100), 213 (34), 215 (13); HRMS (ESI) 210.1125 calcd for C₁₁H₁₆NO₃⁺ (MH⁺), found 210.1052, Δ = -3.4 ppm.


(+)-(2*R*,3*S*)-2-Hydroxy-2-methyl-3-(3-methylpyridin-4-yl)butanoic acid

[†] From the experiment corresponding to Table 1, entry 2.




Ester (-)-(2R,3S)-**6a** (9 mg, 0.0403 mmol) was dissolved in MeOH (0.9 mL) and 1M NaOH (1 mL) was added. The solution was heated at 60 °C for 1 h then concentrated *in vacuo* to remove MeOH. The aqueous solution was acidified to pH 5 with 1M HCl then concentrated under a flow of nitrogen to afford a white solid. MeCN (10 mL) was added and the mixture was sonicated for 15 min then passed through a pad of C18 silica eluting with MeCN. Concentration under a flow of nitrogen afforded (+)-(2R,3S)-2-hydroxy-2-methyl-3-(3-methylpyridin-4-yl)butanoic acid (2.5 mg, 0.0119 mmol, 30%) as a clear oil. Data as above. $[\alpha]_D^{20} +31.6$ ($c = 0.25$, MeCN).

(-)-(2S,3S)-2-Hydroxy-2-methyl-3-(3-methylpyridin-4-yl)butanoic acid



Ester (+)-(2S,3S)-**6b** (13 mg, 0.0582 mmol) was dissolved in MeOH (1.3 mL) and 2 M NaOH (1.3 mL) was added. The solution was heated at 60 °C for 1 h then concentrated *in vacuo* to remove all MeOH. The aqueous solution was acidified to pH 5 with 1 M HCl then concentrated *in vacuo* to afford a white solid. MeCN (15 mL) was added and the mixture was sonicated for 15 min then passed through a pad of C18 silica eluting with MeCN to afford (-)-(2S,3S)-2-hydroxy-2-methyl-3-(3-methylpyridin-4-yl)butanoic acid (10 mg, 0.0478 mmol, 82%) as a clear oil. Data as above. $[\alpha]_D^{20} -0.5$ ($c = 1.0$, MeCN).


(2R*,3S*)- and (2S*,3S*)-2-Hydroxy-2-methyl-3-(3-carboxypyridin-4-yl)butanoic acid, 2a and 2b



2-Hydroxy-2-methyl-3-(3-methylpyridin-4-yl)butanoic acid (16 mg, 0.076 mmol, 1 eq., *dr* 45:55) was dissolved in 1 M NaOH (1.6 mL) and stirred at room temperature for 5 min. KMnO₄ (48 mg, 0.304 mmol, 4 eq.) was added and the mixture was heated at 100 °C for 1 h. After allowing to cool to room temperature, MeOH (10 mL) was added and the MnO₂ precipitate was removed by filtering under suction. The filtrate was concentrated *in vacuo* to afford a white solid. Salt removal of an aqueous solution by Ziptip[®] and concentration under a flow of nitrogen, afforded diacid **3** (17.5 mg, 0.0711 mmol, 95%, *dr* 45:55) as a white solid. R_f 0.15 (MeCN/H₂O, 4:1); mp >250 °C (H₂O); $\nu_{\max}/\text{cm}^{-1}$ (neat)


3397 (OH), 1603 (C=O), 1571 (C=O), 1397 (CH), 1387 (CH), 1163 (C-O); **(2R*,3S*)-diacid 2a (minor component)**: δ_{H} (D₂O, 400 MHz) 8.59 (1H, s, NCH), 8.53 (1H, d, *J* 5.8 Hz, NCHCH), 7.68 (1H, d, *J* 5.4 Hz, NCHCH), 3.82 (1H, q, *J* 7.2 Hz, ArCH), 1.30 (3H, d, *J* 7.1 Hz, ArCHCH₃). δ_{C} (D₂O, 100 MHz) 175.4 (s), 173.6 (s), 162.8 (d), 162.7 (d), 149.0 (d), 119.6 (s), 119.6 (s), 77.4 (d), 41.1 (q), 23.5 (q), 15.1 (q). **(2S*,3S*)-diacid 2b (major component)**: δ_{H} (D₂O, 400 MHz) 8.55 (1H, s, NCH), 8.51 (1H, d, *J* 5.7 Hz, NCHCH), 7.66 (1H, d, *J* 5.4 Hz, NCHCH), 3.80 (1H, q, *J* 6.4 Hz, ArCH), 1.39 (3H, d, *J* 7.2 Hz, ArCHCH₃), 1.39 (3H, s, ArCH₃); δ_{C} (D₂O, 100 MHz) 170.2 (s), 170.1 (s), 149.6 (d), 146.9 (d), 145.9 (d), 127.8 (s), 122.9 (s), 77.5 (s), 41.6 (q), 21.5 (q), 14.3 (q); MS (ESI) *m/z* 281 (22), 241 (13), 240 (100, MH⁺); HRMS (ESI) 240.0866 calcd for C₁₁H₁₄NO₅⁺ (MH⁺), found 240.0870, Δ = +1.6 ppm.

(+)-(2R,3S)-2-Hydroxy-2-methyl-3-(3-carboxypyridin-4-yl)butanoic acid, 2a



(+)-(2R,3S)-2-Hydroxy-2-methyl-3-(3-methylpyridin-4-yl)butanoic acid (2.0 mg, 0.00956 mmol, 1 eq.) was dissolved in 1 M NaOH (0.5 mL) and stirred at room temperature for 5 min. KMnO₄ (6 mg, 0.0382 mmol, 4 eq.) was added and the mixture was heated at 100 °C for 1 h. After allowing to cool to room temperature, MeOH (5 mL) was added and the MnO₂ precipitate was removed by filtration under suction. The filtrate was concentrated *in vacuo* to remove all MeOH. After neutralisation to pH 5 using 1M HCl, the aqueous solution was concentrated under a flow of nitrogen. Salt removal from an aqueous solution by Ziptip[®] and purification by reverse phase (C18 silica) HPLC (MeCN/H₂O, 9:1) afforded *diacid* (+)-(2R,3S)-2a (1.9 mg, 0.00794 mmol, 83%) as a white solid. Data as above. mp >250 °C (H₂O); $[\alpha]_{\text{D}}^{20} +12.8$ (*c* = 0.20, H₂O).

(+)-(2S,3S)-2-Hydroxy-2-methyl-3-(3-carboxypyridin-4-yl)butanoic acid, 2b



(-)-(2S,3S)-2-Hydroxy-2-methyl-3-(3-methylpyridin-4-yl)butanoic acid (10 mg, 0.0478 mmol, 1 eq.) was dissolved in 1 M NaOH (1 mL) and stirred at room temperature for 5 min. KMnO₄ (30 mg, 0.191 mmol, 4 eq.) was added and the mixture was heated at 100 °C for 1 h. After allowing to cool to room temperature, MeOH (5 mL) was added and the MnO₂ precipitated was removed by filtration under


suction. The filtrate was concentrated *in vacuo* to remove all MeOH. After neutralisation to pH 5 with 1M HCl (aq.) the aqueous solution was concentrated under a flow of nitrogen. Salt removal from an aqueous solution by Ziptip[®] and purification by reverse phase (C18 silica) HPLC (MeCN/H₂O, 9:1), afforded *diacid* (+)-**2b** (2.7 mg, 0.0113 mmol, 24%) as a white solid. Data as above. mp >250 °C (H₂O); [α]_D²⁰ +6.7 (*c* = 0.25, H₂O).

References

1. Zhang, Z.; Zhang, J.; Tan, J.; Wang, Z. *J. Org. Chem.* **2008**, *73*, 5180-5182.


HPLC Chromatograms

Esters **6a** and **6b** (*dr* 45:55) using a Chiralcel IC column.




Peak 1 – R_t = 21.1 min, (-)-(2*R*,3*S*)-ester **6a**; **Peak 2** – R_t = 27.3 min, (+)-(2*S*,3*R*)-ester **6a**; **Peak 3** – R_t = 29.5 min, (2*R**,3*R**)-ester **6b**; **Peak 4** – R_t = 31.7 min, (2*R**,3*R**)-ester **6b**. **Conditions**; Chiralcel IC; 5 μ m; Column Size: 0.46 cm (I.D.) \times 25 cm (L); Column number: IC00CE-LL027; Temperature: 10 $^{\circ}$ C; Flow Rate: 1.2 mL/min; Injection: 5 μ L; Solvent: *n*-hexane/IPA = 85:15; Sample conc.: 10 mg/ml (IPA).

Esters **6a** and **6b** (*dr* 45:55) using a Chiralcel ODH column.




Peak 1 – R_t = 21.3 min, (+)-(2*S*,3*S*)-ester **6b**; **Peak 2** – R_t = 26.6 min, (+)-(2*S*,3*R*)- and (-)-(2*R*,3*S*)-esters **6a**; **Peak 3** – R_t = 30.2 min, (-)-(2*R*,3*R*)-ester **6b**. **Conditions**; Chiralcel ODH; 5 μ m; Column Size: 0.46 cm (I.D.) \times 25 cm (L); Column number: ODH0CE-KK122; Temp: 8 $^{\circ}$ C; Flow Rate: 0.75 mL/min; Injection: 7 μ L; Solvent: *n*-hexane/IPA, 90:10; Sample conc.: 10 mg/mL (IPA/EtOAc, 9:1).

(-)-(2*R*,3*S*)-Methyl 2-hydroxy-2-methyl-3-(3-methylpyridin-4-yl)butanoate, 6a




Chemical Formula: C₁₂H₁₇NO₃
Molecular Weight: 223.2683




$R_t = 20.2$ min. **Conditions:** Chiralcel IC; 5 μ m; Column Size: 0.46 cm (I.D.) \times 25 cm (L); Column number IC00CE-LL027; Temperature: 10 $^{\circ}$ C; UV wavelength: 250 nm; Flow Rate: 1.2 mL/min; Injection: 5 μ L; Solvent: *n*-hexane/IPA, 85:15; Pressure: 50 bar; Sample Conc. 0.3 mg/mL (IPA).

(+)-(2*S*,3*S*)-Methyl 2-hydroxy-2-methyl-3-(3-methylpyridin-4-yl)butanoate, 6b




Chemical Formula: C₁₂H₁₇NO₃
Molecular Weight: 223.2683




$R_t = 19.1$ min. **Conditions:** Chiralcel OD-H; 5 μ m; Column Size: 0.46 cm (I.D.) \times 25 cm (L); Column number ODH0CE-KK122; Temperature: 8 $^{\circ}$ C; UV wavelength: 254 nm; Flow Rate: 0.9 mL/min; Injection: 1 μ L; Solvent: *n*-hexane/IPA, 95:5; Pressure: 44 bar; Sample Conc. 7 mg/mL (EtOAc/IPA, 1:1).

NMR spectra of Novel Compounds


¹H NMR (CDCl₃, 400 MHz) Diethyl 1-ethoxycarbonyl-1,4-dihydroxy-3-methylpyridine-4-phosphonate, **9**




^{13}C NMR (CDCl_3 , 100 MHz) Diethyl 1-ethoxycarbonyl-1,4-dihydroxy-3-methylpyridine-4-phosphonate, **9**




¹H NMR (CDCl₃, 400 MHz) (±)-3-Methyl-4-[(*E*)-pent-2-en-4-yl]pyridine, **8**




^{13}C NMR (CDCl_3 , 100 MHz) (\pm)-3-Methyl-4-[(*E*)-pent-2-en-4-yl]pyridine, **8**




¹H NMR (CDCl₃, 400 MHz) 3-Methyl-4-[(2*S**,3*S**,4*S**)-2,3-epoxypentan-4-yl]pyridine and methyl-4-[(2*S**,3*S**,4*R**)-2,3-epoxypentan-4-yl]pyridine, **11**




^{13}C NMR (CDCl_3 , 100 MHz) 3-Methyl-4-[(2*S**,3*S**,4*S**)-2,3-epoxypentan-4-yl]pyridine and Methyl-4-[(2*S**,3*S**,4*R**)-2,3-epoxypentan-4-yl]pyridine, **11**




^1H NMR (CDCl_3 , 400 MHz) ($2R^*$, $3S^*$, $4S^*$)- and ($2R^*$, $3S^*$, $4R^*$)-4-(3-Methylpyridin-4-yl)pentane-2,3-diol, **12**




^{13}C NMR (CDCl_3 , 100 MHz) ($2R^*$, $3S^*$, $4S^*$)- and ($2R^*$, $3S^*$, $4R^*$)-4-(3-Methylpyridin-4-yl)pentane-2,3-diol, **12**




^1H NMR (CDCl_3 , 400 MHz) (\pm)-4-(3-Methylpyridin-4-yl)pentane-2,3-dione, 7




^{13}C NMR (CDCl_3 , 100 MHz) (\pm)-4-(3-Methylpyridin-4-yl)pentane-2,3-dione, 7




^1H NMR (CDCl_3 , 400 MHz) ($2S^*$, $3R^*$)- and ($2R^*$, $3R^*$)-Methyl 2-hydroxy-2-methyl-3-(3-methylpyridin-4-yl)butanoate, **6a** and **6b**




^{13}C NMR (CDCl_3 , 100 MHz) ($2S^*,3R^*$)- and ($2R^*,3R^*$)-Methyl 2-hydroxy-2-methyl-3-(3-methylpyridin-4-yl)butanoate, **6a** and **6b**




^1H NMR (CDCl_3 , 400 MHz) (+)-(2*S*,3*S*)-Methyl 2-hydroxy-2-methyl-3-(3-methylpyridin-4-yl)butanoate, **6b**




^{13}C NMR (CDCl_3 , 100 MHz) (+)-(2*S*,3*S*)-Methyl 2-hydroxy-2-methyl-3-(3-methylpyridin-4-yl)butanoate, **6b**




^1H NMR (D_2O , 400 MHz) ($2R^*,3S^*$)- and ($2S^*,3S^*$)-2-Hydroxy-2-methyl-3-(3-methylpyridin-4-yl)butanoic acids




^{13}C NMR (D_2O , 100 MHz) ($2R^*,3S^*$)- and ($2S^*,3S^*$)-2-Hydroxy-2-methyl-3-(3-methylpyridin-4-yl)butanoic acids




^1H NMR (D_2O , 400 MHz) (-)-(2*S*,3*S*)-2-Hydroxy-2-methyl-3-(3-methylpyridin-4-yl)butanoic acid




^{13}C NMR (D_2O , 100 MHz) (-)-(2*S*,3*S*)-2-Hydroxy-2-methyl-3-(3-methylpyridin-4-yl)butanoic acid




^1H NMR (D_2O , 400 MHz) ($2R^*,3S^*$)- and ($2S^*,3S^*$)-2-Hydroxy-2-methyl-3-(3-carboxypyridin-4-yl)butanoic acid, **2a** and **2b**



^{13}C NMR (D_2O , 100 MHz) ($2R^*$, $3S^*$)- and ($2S^*$, $3S^*$)-2-Hydroxy-2-methyl-3-(3-carboxypyridin-4-yl)butanoic acid, **2a** and **2b**



^1H NMR (D_2O , 400 MHz) (+)-(2*S*,3*S*)-2-Hydroxy-2-methyl-3-(3-carboxypyridin-4-yl)butanoic acid, **2b**



^{13}C NMR (D_2O , 100 MHz) (+)-(2*S*,3*S*)-2-Hydroxy-2-methyl-3-(3-carboxypyridin-4-yl)butanoic acid, **2b**

